中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
18期
92-95
,共4页
吸入性肺炎%布地奈德%效果
吸入性肺炎%佈地奈德%效果
흡입성폐염%포지내덕%효과
Aspiration pneumonia%Budesonide%Efficacy
目的:观察布地奈德混悬液雾化吸入治疗吸入性肺炎的效果.方法选择2012年1月~2013年6月杭州市萧山区第一人民医院收治的吸入性肺炎患者42例,按治疗方法不同分为治疗组23例及对照组19例.对照组给予常规氧疗、抗感染、营养支持治疗,治疗组在对照组基础上加用布地奈德混悬液雾化吸入.观察两组治疗效果及治疗前及治疗后3 d、1周的动脉二氧化碳分压(PaCO2)、动脉氧分压(PaO2)、pH值、空腹血糖变化情况.结果①治疗组总有效共20例,无效或进展者3例,总有效率为86.96%;对照组总有效共15例,无效或进展者4例,总有效率为78.95%.两组总有效率比较,差异有统计学意义(P<0.05).②治疗组与对照组治疗前PaCO2比较[(7.10±1.64)mm Hg比(6.97±1.92)mm Hg](1 mm Hg=0.133 kPa),差异无统计学意义(P>0.05);治疗后3 d,治疗组PaCO2水平[(5.76±1.06)mm Hg]低于对照组[(6.78±1.55)mm Hg],差异有统计学意义(P<0.05);治疗后1周,两组PaCO2水平比较,差异无统计学意义(P>0.05).③治疗组与对照组治疗前PaO2比较[(8.10±1.52)mm Hg比(8.21±1.23)mm Hg],差异无统计学意义(P>0.05);治疗后3 d,治疗组PaO2水平[(9.51±1.63)mm Hg]高于对照组[(8.32±1.31)mm Hg],差异有统计学意义(P<0.05);治疗后1周,两组PaO2水平比较,差异无统计学意义(P>0.05).榆两组治疗前及治疗后3 d、1周pH值比较,差异均无统计学意义(P >0.05).虞治疗组与对照组治疗前空腹血糖值[(5.72±1.02)mmol/L比(5.63±1.34)mmol/L]比较,差异无统计学意义(P>0.05);两组治疗后3 d、1周空腹血糖值比较,差异均无统计学意义(P>0.05).结论布地奈德混悬液治疗吸入性肺炎安全、有效。
目的:觀察佈地奈德混懸液霧化吸入治療吸入性肺炎的效果.方法選擇2012年1月~2013年6月杭州市蕭山區第一人民醫院收治的吸入性肺炎患者42例,按治療方法不同分為治療組23例及對照組19例.對照組給予常規氧療、抗感染、營養支持治療,治療組在對照組基礎上加用佈地奈德混懸液霧化吸入.觀察兩組治療效果及治療前及治療後3 d、1週的動脈二氧化碳分壓(PaCO2)、動脈氧分壓(PaO2)、pH值、空腹血糖變化情況.結果①治療組總有效共20例,無效或進展者3例,總有效率為86.96%;對照組總有效共15例,無效或進展者4例,總有效率為78.95%.兩組總有效率比較,差異有統計學意義(P<0.05).②治療組與對照組治療前PaCO2比較[(7.10±1.64)mm Hg比(6.97±1.92)mm Hg](1 mm Hg=0.133 kPa),差異無統計學意義(P>0.05);治療後3 d,治療組PaCO2水平[(5.76±1.06)mm Hg]低于對照組[(6.78±1.55)mm Hg],差異有統計學意義(P<0.05);治療後1週,兩組PaCO2水平比較,差異無統計學意義(P>0.05).③治療組與對照組治療前PaO2比較[(8.10±1.52)mm Hg比(8.21±1.23)mm Hg],差異無統計學意義(P>0.05);治療後3 d,治療組PaO2水平[(9.51±1.63)mm Hg]高于對照組[(8.32±1.31)mm Hg],差異有統計學意義(P<0.05);治療後1週,兩組PaO2水平比較,差異無統計學意義(P>0.05).榆兩組治療前及治療後3 d、1週pH值比較,差異均無統計學意義(P >0.05).虞治療組與對照組治療前空腹血糖值[(5.72±1.02)mmol/L比(5.63±1.34)mmol/L]比較,差異無統計學意義(P>0.05);兩組治療後3 d、1週空腹血糖值比較,差異均無統計學意義(P>0.05).結論佈地奈德混懸液治療吸入性肺炎安全、有效。
목적:관찰포지내덕혼현액무화흡입치료흡입성폐염적효과.방법선택2012년1월~2013년6월항주시소산구제일인민의원수치적흡입성폐염환자42례,안치료방법불동분위치료조23례급대조조19례.대조조급여상규양료、항감염、영양지지치료,치료조재대조조기출상가용포지내덕혼현액무화흡입.관찰량조치료효과급치료전급치료후3 d、1주적동맥이양화탄분압(PaCO2)、동맥양분압(PaO2)、pH치、공복혈당변화정황.결과①치료조총유효공20례,무효혹진전자3례,총유효솔위86.96%;대조조총유효공15례,무효혹진전자4례,총유효솔위78.95%.량조총유효솔비교,차이유통계학의의(P<0.05).②치료조여대조조치료전PaCO2비교[(7.10±1.64)mm Hg비(6.97±1.92)mm Hg](1 mm Hg=0.133 kPa),차이무통계학의의(P>0.05);치료후3 d,치료조PaCO2수평[(5.76±1.06)mm Hg]저우대조조[(6.78±1.55)mm Hg],차이유통계학의의(P<0.05);치료후1주,량조PaCO2수평비교,차이무통계학의의(P>0.05).③치료조여대조조치료전PaO2비교[(8.10±1.52)mm Hg비(8.21±1.23)mm Hg],차이무통계학의의(P>0.05);치료후3 d,치료조PaO2수평[(9.51±1.63)mm Hg]고우대조조[(8.32±1.31)mm Hg],차이유통계학의의(P<0.05);치료후1주,량조PaO2수평비교,차이무통계학의의(P>0.05).유량조치료전급치료후3 d、1주pH치비교,차이균무통계학의의(P >0.05).우치료조여대조조치료전공복혈당치[(5.72±1.02)mmol/L비(5.63±1.34)mmol/L]비교,차이무통계학의의(P>0.05);량조치료후3 d、1주공복혈당치비교,차이균무통계학의의(P>0.05).결론포지내덕혼현액치료흡입성폐염안전、유효。
Objective To observe the efficacy of Budesonide atomization inhalation in the treatment of aspiration pneumonia. Methods 42 cases of patients with aspiration pneumonia in the First People's Hospital of Xiaoshan District in Hangzhou City from January 2012 to June 2013 were selected and divided into treatment group (23 cases) and con-trol group (19 cases) according to different treating methods. The control group was treated with routine therapies in-cluding oxygen therapy, anti-infection and nutrition support therapy; the treatment group was treated with Budesonide suspension aerosol inhalation on the basis of control group. The treatment efficacy between the two groups was ob-served; the PaCO2, PaO2, pH value, fasting blood-glucose between the two groups were compared. Results ①20 cases of total effective, 3 cases of nullity or progress were found in treatment group, the total effective rate was 86.96%;15 cas-es of total effective, 4 cases of nullity or progress were found in control group, the total effective rate was 78.95%. The difference of total effective rate between the two groups was statistically significant (P<0.05). ②The difference of Pa-CO2 before the treatment between treatment group and control group [(7.10±1.64) mm Hg vs (6.97±1.92) mm Hg] (1 mm Hg=0.133 kPa) was not statistically significant (P>0.05);PaCO2 level in treatment group 3 days after the treatment [(5.76±1.06) mm Hg] was lower than that in control group [(6.78±1.55) mm Hg], the difference was statistically significant (P<0.05); the difference of PaCO2 between the two groups 1 week after the treatment was not statistically significant (P>0.05).③The difference of PaO2 before the treatment between the treatment group and control group [(8.10±1.52) mm Hg vs (8.21±1.23) mm Hg] was not statistically significant (P>0.05);PaO2 level in treatment group 3 days after the treatment [(9.51±1.63) mm Hg] was higher than that in control group [(8.32±1.31) mm Hg], the difference was statistically signifi-cant (P< 0.05); the difference of PaO2 between the two groups 1 week after the treatment was not statistically signifi-cant (P>0.05).④The difference of pH level between the two groups before the treatment and 3 days, 1 week after the treatment was not statistically significant (P> 0.05).⑤The difference of fasting blood-glucose between the treatment group and control group [(5.72±1.02) mmol/L vs (5.63±1.34) mmol/L] before the treatment was not statistically significant (P>0.05);the difference of fasting blood-glucose between the two groups 3 days and 1 week after the treatment was not statistically significant (P>0.05). Conclusion Budesonide in the treatment of aspiration pneumonia is safe and effective.